Exocrine Pancreatic Insufficiency Following Asparaginase-induced Pancreatitis in Pediatric Acute Lymphoblastic...

Area of Science:

• Oncology
• Gastroenterology
• Pediatric Medicine

Background:

• Asparaginase is a critical component in treating pediatric acute lymphoblastic leukemia (ALL).
• Asparaginase administration is associated with adverse effects, notably asparaginase-associated pancreatitis (AAP).
• Exocrine pancreatic insufficiency (EPI) is a known complication of pancreatitis but has not been previously documented in pediatric leukemia patients.

Purpose of the Study:

• To document cases of severe necrotizing asparaginase-associated pancreatitis (AAP) followed by exocrine pancreatic insufficiency (EPI) in pediatric leukemia patients.
• To raise awareness of the association between AAP and subsequent EPI in this population.
• To encourage timely identification and intervention for EPI in pediatric leukemia survivors.

Main Methods:

• Retrospective case series.
• Description of three pediatric patients treated for acute lymphoblastic leukemia.
• Detailed clinical course including diagnosis and management of severe necrotizing asparaginase-associated pancreatitis and subsequent exocrine pancreatic insufficiency.

Main Results:

• Three pediatric patients developed severe necrotizing AAP during leukemia treatment.
• All three patients subsequently developed exocrine pancreatic insufficiency (EPI) of varying duration.
• EPI, if undiagnosed, can lead to significant nutritional deterioration.

Conclusions:

• Severe necrotizing AAP can lead to the development of EPI in pediatric patients with acute lymphoblastic leukemia.
• Increased clinical awareness is crucial for the early detection of EPI following AAP in this cohort.
• Prompt diagnosis and management of EPI are essential to prevent nutritional complications in pediatric leukemia survivors.